Related by context. All words. (Click for frequent words.) 68 Diabetic Neuropathy 67 alpha1 antitrypsin deficiency 66 beta 1a 66 MELAS 65 Meets Primary Endpoint 65 Initiates Clinical Trial 65 Liprotamase 65 Aflibercept 64 CYT# potent vascular disrupting 64 Tyrosine Kinase Inhibitor 64 neuropathic pain spasticity 64 Protein Kinase C 64 Sudhir Agrawal D.Phil 64 Investigational Treatment 64 Receives Orphan Drug Designation 64 Familial Adenomatous Polyposis FAP 64 treat chronic sinusitis 64 Novel Oral 63 Decitabine 63 Myelodysplastic Syndrome MDS 63 diarrhea predominant irritable 63 Myelofibrosis 63 Orally administered 63 Prolongs Survival 63 Soft Tissue Sarcoma 63 Acute Myeloid Leukaemia AML 63 thalidomide Thalomid 63 Ecallantide 63 Antiviral Therapy 63 myelodysplastic myeloproliferative diseases 63 hypereosinophilic syndrome 63 Dyskinesia 63 Initiates Phase II 63 acetonide FA 63 R Saizen R 62 HepDirect prodrug 62 Antigen Specific 62 Squalamine 62 Progressive Multifocal Leukoencephalopathy 62 exocrine pancreatic insufficiency EPI 62 Romidepsin 62 NASH Huntington 62 leukemia AML 62 prokinetic agent 62 Glioblastoma Multiforme 62 GW# [003] 62 Phase 2b Clinical Trial 62 Severe Sepsis 62 Mouse Model 62 lexidronam injection 62 complement inhibitor eculizumab 62 Kinase Inhibitor 62 psoriasis rheumatoid arthritis 62 novel therapeutic antibodies 62 MKC# MT 62 Immunotherapeutic 62 Teriflunomide 62 vinorelbine tartrate 62 relapsed leukemia 62 Carbidopa 62 TTR amyloidosis 62 ® lenalidomide 62 Maribavir 62 chronic eosinophilic leukemia 62 Daclizumab 62 benign prostatic hypertrophy BPH 62 cetuximab Erbitux R 62 Successfully Completes Phase 62 Chronic Myelogenous Leukemia 62 Lupus Nephritis 62 DP VPA 62 inhalation powder 62 Completes Patient Enrollment 62 Hsp# Inhibitor 62 metastatic malignant 62 humanised monoclonal antibody 62 Morquio 62 Initiates Enrollment 62 antibody MAb 62 abacavir Ziagen 61 selective A2A adenosine receptor 61 vapreotide acetate 61 Cloretazine 61 gastrointestinal stromal tumor GIST 61 Oral Fingolimod 61 PEGylated Fab fragment 61 Idiopathic Pulmonary Fibrosis 61 rheumatoid arthritis RA psoriatic 61 erythematosus 61 Recombinant interferon alpha 61 Acute Renal Failure 61 MTP inhibitor 61 erlotinib Tarceva ® 61 Angioedema 61 non nucleoside inhibitor 61 Hepatocellular 61 Lymphoid 61 Trinam 61 Mycophenolate Mofetil 61 Aviptadil 61 psoriatic arthritis PsA 61 Drug Candidate 61 targeted antifolate 61 humanized monoclonal 61 refractory chronic lymphocytic 61 SYN# 61 Enzastaurin 61 Bronchiectasis 61 Mucopolysaccharidosis 61 Systemic lupus erythematosus SLE 61 Fabry Disease 61 relapsing multiple sclerosis 61 RNA antagonists 61 syndrome IBS 61 HDAC Inhibitor 61 INSPIRE Trial Phase III 61 Graft Versus Host 61 Pegloticase 61 Lymphocytic 61 mitoxantrone plus 61 Submits NDA 61 Vidaza azacitidine 61 Bosutinib 61 Multiple Ascending Dose 61 candidates Azedra TM 61 Serostim ® 61 MAGE A3 ASCI 61 ergot derivatives 61 Fingolimod 61 Torisel temsirolimus 61 HLA DR4 61 acyclovir Lauriad R 61 Initiate Phase 61 RhuDex R 61 Dehydrogenase 61 Phase 2b Trial 61 Presents Preclinical Data 61 Azacitidine 61 histone deacetylase HDAC inhibitor 61 RhuDex 61 IV Busulfex 60 Safinamide 60 Oncolytic 60 Monoclonal antibody 60 Xyfid TM 60 dasatinib Sprycel ® 60 Initiates Dosing 60 Shows Promise Against 60 TNF Tumor Necrosis Factor 60 Achieves Primary Endpoint 60 Omacetaxine 60 Factor VIIa 60 Atypical Hemolytic Uremic Syndrome 60 Dalbavancin 60 uremic pruritus 60 Patients Treated With 60 aurora kinase 60 tumors GIST 60 dual endothelin receptor antagonist 60 fibrotic disorders 60 receptor tyrosine kinase inhibitor 60 aripiprazole Abilify 60 thetreatment 60 Complicated Skin 60 orally administered inhibitor 60 Initiates Phase III 60 proteasome inhibitor 60 small molecule tyrosine 60 gefitinib Iressa 60 peripherally acting 60 Granulocyte Colony Stimulating Factor 60 Phase #b/#a clinical 60 RNA antagonist 60 Epratuzumab 60 Granted Orphan Drug 60 PF # [002] 60 constipation predominant irritable bowel 60 Chronic Lymphocytic Leukemia CLL 60 Leukemias 60 Orally Active 60 systemic juvenile idiopathic 60 biliary tract cancer 60 Gleevec resistant 60 Files IND 60 bladder ovarian 60 multiple sclerosis Crohn disease 60 treat benign prostatic 60 oral nucleoside analogue 60 mGluR2 positive 60 TKB# 60 chronic granulomatous disease 60 dyskinetic 60 AKT inhibitor 60 IMiDs R 60 EVIZON TM 60 novel emulsion formulation 60 idiopathic thrombocytopenic purpura ITP 60 Phase IIa Clinical Trial 60 Natalizumab 60 Pazopanib 60 Submits Response 60 Protease 60 Respiratory Syncytial Virus RSV 60 SSc 60 anthracycline containing 60 Glycosylation 60 Huntingtons disease 60 transthyretin amyloidosis 60 Campath alemtuzumab 60 AVONEX ® 60 RTP #i 60 metastatic gastric 60 pregabalin Lyrica 60 KSP inhibitor 60 Bosentan 60 Tumor Necrosis Factor 60 Investigational Oral 60 ALN HPN 60 Fludara ® 60 oropharyngeal candidiasis OPC 60 selectively inhibited 60 recurrent glioblastoma multiforme 60 R lenalidomide 60 Valproic acid 60 monoclonal anti 60 Factor Receptor 60 adalimumab Humira 60 herpetic keratitis 60 Phase IIb Clinical Trial 60 FDA Accepts 60 Begins Dosing 60 Dementia Related Psychosis 60 sargramostim 59 arthritis PsA 59 pan HDAC inhibitor 59 Slow Progression 59 nucleoside analog 59 cystic fibrosis chronic pancreatitis 59 Zorbtive TM 59 denileukin diftitox 59 IND Application 59 Chronic Sinusitis 59 Chronic Prostatitis 59 CEQ# 59 AAG geldanamycin analog 59 thrombotic thrombocytopenic purpura 59 Polyneuropathy 59 Bezielle 59 IAP inhibitor 59 Subtypes 59 polycythemia vera essential thrombocythemia 59 essential thrombocythemia ET 59 myeloproliferative neoplasms MPNs 59 Initiate Clinical Trial 59 Parnate 59 familial amyloidotic polyneuropathy FAP 59 RhuDex TM 59 Noxafil 59 CDP# 59 cause cardiac channelopathies 59 PEGylated interferon beta 1a 59 Maven Semantic 59 intranasal formulation 59 AVAPRO 59 HQK 59 dasatinib Sprycel 59 Reports Preclinical Data 59 SPRYCEL ® 59 PNP inhibitor 59 rivastigmine Exelon 59 Hypertriglyceridemia 59 1 proteinase inhibitor 59 Pharmacokinetics PK 59 Enzyme Replacement Therapy 59 fibrosing 59 Friedreich Ataxia FRDA 59 Plaque Psoriasis 59 itraconazole Sporanox 59 Actinic Keratosis 59 metastatic malignant melanoma 59 PRN FDA Approves 59 Zenvia ™ 59 chronic myeloid 59 acute myeloid 59 Intravenous immunoglobulin 59 ACTIQ ® 59 Vitrasert R 59 CCR9 antagonist 59 oral Hsp# inhibitor 59 PEGylated anti 59 Hereditary angioedema 59 Adjuvant Treatment 59 Congenital Emphysema 59 Initiates Clinical Trials 59 Lubiprostone 59 synthetic peptide containing 59 HeFH 59 LymphoStat B TM 59 myelofibrosis polycythemia vera 59 PEG IFN 59 BCG refractory carcinoma 59 cromolyn sodium 59 Cancidas 59 targeted radiotherapeutic 59 pouchitis 59 severe malignant osteopetrosis 59 RNAi therapeutic targeting 59 Dacogen decitabine 59 B Cell Lymphoma 59 sapropterin dihydrochloride 59 Systemic Sclerosis 59 rheumatoid arthritis psoriatic arthritis 59 T#I [002] 59 Pemphigus 59 oral prodrug 59 aerosolized KL4 surfactant 59 precursor acute lymphoblastic 59 Mimetics 59 basal cell carcinoma BCC 59 uricase 59 Chronic lymphocytic leukemia 59 NS#/#A protease 59 Fc fusion protein 59 Rheumatoid 59 Chronic Myeloid Leukemia 59 parkinson disease 59 Alemtuzumab 59 lupus scleroderma 59 constipation predominant IBS 59 included exfoliative dermatitis 59 Martin Nicklasson CEO 59 Acute Bacterial Sinusitis ABS 59 sunitinib Sutent 59 Peripheral Arterial 59 Files Investigational 59 Vitrasert ® 59 Myoblast 59 Irinotecan 59 immunotherapeutic vaccine 59 IAP inhibitors 59 pediatric acute lymphoblastic 59 Receive Milestone Payment 59 Tasimelteon 59 Major Depressive Disorder MDD 59 Onalta TM 59 triciribine phosphate monohydrate 59 commercialize deforolimus 59 chronic constipation CC 59 Initiates Clinical 59 rheumatoid arthritis osteoarthritis ankylosing 59 fosbretabulin 59 Ph + acute lymphoblastic 59 AA Amyloidosis 59 Motexafin Gadolinium 59 Cimzia TM 59 YONDELIS 59 Luteinizing Hormone Releasing Hormone 59 Submits IND 59 Juvenile Idiopathic Arthritis JIA 59 nephropathic cystinosis 59 Idiopathic Pulmonary Fibrosis IPF 59 etanercept Enbrel 59 idursulfase 59 Pamidronate 59 LHON 59 Nipent R 59 Trovax 59 TRX1 58 diabetic gastroparesis 58 HCV polymerase 58 generation purine nucleoside 58 CTAP# Capsules 58 iobenguane 58 JAK2 Inhibitor 58 Disease IBD 58 progressive neurodegenerative 58 tiapamil 58 Tesmilifene 58 Tigecycline 58 Chemokine Receptor 58 targeting CD# 58 prucalopride 58 Peginterferon alfa 2b 58 hereditary spastic paraplegia 58 cyclin dependent kinase inhibitor 58 Acute Attacks 58 Cytochrome P# 58 inflammatory demyelinating 58 Onconase 58 FDA APPROVES 58 transthyretin TTR mediated amyloidosis 58 chronic rheumatic 58 NAGS deficiency 58 RhuDex ® 58 novel VDA molecule 58 JAK2 inhibitor 58 liposomal formulation 58 constipation OIC 58 Ceflatonin R 58 alfa 2b 58 IN PATIENTS WITH 58 sodium stibogluconate 58 lumiliximab 58 Interferon beta 58 Epstein Barr Virus EBV 58 Intra arterial 58 FOLOTYN ® 58 Lenocta TM 58 toenail onychomycosis 58 Polymorphisms 58 histone deacetylase inhibitor 58 metastatic neuroendocrine tumors 58 atypical hemolytic uremic syndrome 58 chronic idiopathic thrombocytopenic purpura 58 Ischemic 58 Hepatocellular Carcinoma HCC 58 Presents Positive 58 small molecule chemotherapeutic 58 Xanafide 58 SNT-MC#/idebenone 58 Slows Progression 58 Primary Immunodeficiency 58 Epidermal Growth Factor Receptor 58 HBeAg + 58 Bucindolol 58 oral proteasome inhibitor 58 Niemann Pick disease 58 Epoetin 58 methylnaltrexone bromide 58 Anavex #-# 58 systemic lupus erythematosus psoriasis 58 lymphoid malignancies 58 FOR FURTHER INFORMATION ABOUT 58 Fast Track Status 58 intravenous AAT 58 posterior uveitis 58 evaluating picoplatin 58 1 Antitrypsin Deficiency 58 Philadelphia Chromosome Positive 58 Endocrinol 58 Vidaza R 58 Myeloid 58 brivanib 58 alkylating agent 58 MBRX 58 Conjugate 58 reslizumab 58 rxRNA 58 Darinaparsin 58 PsA 58 SinuNase TM 58 Receptor Agonist 58 torsade de pointes 58 rheumatoid arthritis inflammatory bowel 58 Irritable Bowel 58 Leber Hereditary Optic Neuropathy 58 pulmonary hypertension PH 58 Alfacell proprietary ribonuclease 58 hepatorenal syndrome 58 Ribavirin causes 58 Commences Phase 58 phase III isavuconazole 58 Shows Statistically Significant 58 Pregabalin 58 HSP# inhibitor 58 Vicriviroc 58 peritumoral brain edema 58 Saforis 58 Anidulafungin 58 glutamic acid decarboxylase 58 Gets FDA Clearance 58 Serostim R 58 rheumatoid arthritis systemic lupus 58 alpha1 proteinase inhibitor 58 Phase 2a Trial 58 Evoltra ® 58 irreversible inhibitor 58 Neuroprotection 58 LymphoStat B belimumab 58 rufinamide 58 Nilotinib 58 Loxapine 58 Prodrug 58 Fluconazole 58 multiple sclerosis lupus 58 Alzheimer disease cognitive impairment 58 humanized interleukin 6 58 Hervé Hoppenot President 58 Epstein Barr Virus 58 Sprycel dasatinib 58 bevacizumab Avastin ® 58 alpha1 antitrypsin AAT deficiency 58 Aryplase 58 Kuvan sapropterin dihydrochloride 58 Begin Clinical Trials 58 Novel Compound 58 refractory acute myeloid 58 developing Bicifadine serotonin 58 activin receptor type 58 Phase IIb Trial 58 mTOR mammalian target 58 visilizumab 58 GVAX ® 58 Nonalcoholic fatty liver 58 triphendiol 58 mGluR2 NAM 58 PKC# 58 rhMBL 58 novel histone deacetylase 58 Pivotal Phase III 58 transcranial Doppler ultrasound 58 benign prostatic hypertrophy 58 Arrhythmogenic 58 syngeneic 58 myeloproliferative disorders 58 Velcade bortezomib 58 ALN PCS 58 Gamunex C 58 idiopathic thrombocytopenic purpura 58 Pimavanserin 58 formerly LymphoStat B 58 polycythemia vera PV 57 non hodgkin lymphoma 57 hemorrhagic cystitis 57 TLR9 agonist 57 secretory phospholipase A2 57 IPL# 57 PLA2 57 Bazedoxifene 57 neurogenic bladder 57 Systemic Lupus Erythematosus 57 Hepatic Encephalopathy 57 mGluR5 antagonist 57 Pompe Disease 57 relapsing remitting MS RRMS 57 Mantle Cell Lymphoma 57 SinuNase ™ 57 Cethromycin 57 Squamous 57 patientswith 57 Aptamer 57 Janus kinase 57 imatinib Gleevec ® 57 Vandetanib 57 lysosomal storage diseases 57 Dasatinib 57 Chronic Lymphocytic Leukemia 57 DEB# 57 Newly Diagnosed Multiple Myeloma 57 neutropenia dehydration dyspnea 57 Multiple Myeloma MM 57 Presents Preclinical 57 Amgen Neulasta R 57 Recombinant Human 57 Randomized Phase 57 myasthenia gravis MG 57 fluoropyrimidine 57 volociximab 57 CIMZIA TM certolizumab pegol 57 mertansine 57 Receives Orphan Drug 57 Personalized Immunotherapy 57 Ozarelix 57 chronic thromboembolic pulmonary 57 ara C 57 tafamidis 57 #:#-# [031] 57 MCSP respectively 57 hyaluronidase enzyme 57 Lambert Eaton Myasthenic 57 docetaxel Taxotere ® 57 ANCA associated 57 sorafenib Nexavar 57 IL# PE#QQR 57 Secretase 57 dyskeratosis congenita 57 Gleevec imatinib mesylate 57 myeloproliferative neoplasms 57 ALN TTR 57 trastuzumab Herceptin R 57 rhIGF-I/rhIGFBP-3 57 debilitating autoimmune 57 Pathogenesis 57 Renal Cancer 57 Pafuramidine 57 anticholinergic agents 57 Deferiprone 57 Adjunctive Therapy 57 Gene Linked 57 Panzem R NCD 57 basiliximab 57 lucinactant 57 induced macular edema 57 SUVN 57 induce orthostatic hypotension 57 Chronic Bronchitis 57 Parkinson Disease PD 57 lintuzumab SGN 57 Inflammatory Diseases 57 huN# DM1 57 Fx #A 57 lymphocytic leukemia 57 neuroendocrine cancers 57 metastatic GIST 57 Initiates Phase 57 Silodosin 57 Acute myeloid leukemia 57 P#X# antagonist 57 novel immunomodulatory 57 ATTR PN 57 Skin Disorders 57 angiogenesis inhibition 57 opioid induced constipation OIC 57 XL# anticancer compounds 57 KRN# 57 XL# XL# 57 Primary Biliary Cirrhosis 57 Kuvan R 57 Schizoaffective Disorder 57 E1 INT TM 57 DNA demethylating agent 57 5 HT2A inverse 57 non splenectomized 57 Non Hodgkin 57 Cutaneous T 57 Clinical Trials Consortium 57 somatostatin analogue 57 Dr. Aiping Young 57 Temodar ® 57 Preclinical Study 57 Mylan Receives Approval 57 VitiGam 57 Associated Adipose Redistribution 57 lysosomal storage disease 57 Genetic Variation 57 antisense inhibitor 57 PrevOnco 57 Kinase Inhibitors 57 Tezampanel 57 rare autosomal recessive 57 Certolizumab pegol 57 ketolide antibiotic 57 Interstitial cystitis 57 BRAF V#E 57 Cloretazine ® 57 Monoclonal 57 Relapsed Refractory 57 CLL SLL 57 Copegus ribavirin 57 congenital deficiency 57 Lennox Gastaut syndrome 57 R abatacept 57 acute promyelocytic leukemia 57 myeloid metaplasia 57 myotonic muscular dystrophy 57 BioSante Pharmaceuticals Announces 57 Myelodysplastic Syndrome 57 Voreloxin 57 HCV RNA polymerase 57 ATL# [002] 57 psoriasis Crohn disease 57 cytomegalovirus infection 57 dextromethorphan quinidine 57 systemic fungal infections 57 Pancreatic 57 advanced neuroendocrine tumors 57 Kamada AAT 57 lamotrigine Lamictal 57 DURIN TM 57 symptomatic benign prostatic 57 IgG1 monoclonal antibody 57 Clinical Outcome 57 Initiates Phase 2b 57 Previously Treated 57 mediated inhibition 57 Aptivus ® 57 Copegus ® 57 Cardiotoxicity 57 systemic autoimmune 57 Navelbine ® 57 Hemorrhagic 57 Parkinson disease levodopa induced 57 Incretin 57 Pemetrexed 57 esophageal candidiasis 57 aggressive systemic mastocytosis 57 multicenter Phase II 57 Degenerative Disc Disease 57 Severe Primary IGFD 57 factor TNF receptor 57 alefacept 57 dihydrochloride 57 Juvenile Idiopathic Arthritis 57 immunomodulatory therapy 57 small molecule thrombopoietin 57 efalizumab 56 Rivastigmine 56 Post Herpetic Neuralgia 56 optica 56 Etanercept 56 Ganciclovir 56 mastocytosis 56 cell lymphoma CTCL 56 SomatoKine 56 Clofarabine 56 TLR9 agonists 56 Novel Inhibitor 56 Myelodysplastic Syndromes 56 Acute Myelogenous Leukemia 56 mecasermin 56 Non Alcoholic Steatohepatitis 56 Completes Dosing 56 Inflammatory Markers 56 J Consult Clin 56 relapsed CLL 56 Thrombotic 56 Cytomegalovirus 56 mycosis fungoides 56 murine model 56 pemphigus vulgaris 56 PDE4 56 baminercept 56 successfully commercialize Iluvien 56 advanced metastatic renal 56 Acute Promyelocytic Leukemia 56 highly selective inhibitor 56 Multaq dronedarone 56 selective antagonist 56 oral antiviral 56 protein misfolding diseases 56 regulator CFTR gene 56 Subtype 56 malignant lymphomas 56 PLX MS 56 Spiegelmer ® 56 subependymal giant cell 56 lysosomal storage disorder 56 erlotinib Tarceva 56 ropinirole Requip 56 Oral Calcitonin 56 FLT3 56 spinal muscular atrophy SMA 56 pan histone deacetylase 56 Fibrillex TM 56 Inflammatory Arthritis 56 Completes Enrollment 56 MOVIPREP R 56 Immune Responses 56 diabetic kidney 56 Interferon gamma 56 octreotide implant 56 hereditary degenerative 56 novel prodrug 56 PDE4 inhibitor 56 Atopic Dermatitis 56 multiple myeloma MM 56 Neovascular Age Related Macular 56 autosomal recessive disease 56 alfa 2a 56 Chemotherapy Induced 56 Malignant Melanoma 56 Chronic Myelogenous Leukemia CML 56 sorafenib tablets 56 idiopathic myelofibrosis 56 Frozen Shoulder Syndrome 56 neuro inflammatory disorders 56 overactive bladder VANTAS R 56 ADP receptor antagonist 56 metastatic renal 56 Hodgkin lymphoma HL 56 post herpetic neuralgia PHN 56 telaprevir VX 56 Autoimmune Disease 56 insulin glulisine 56 Phase 2a Clinical Trial 56 Diffuse Large B 56 sJIA 56 Generalized Anxiety Disorder 56 Reminyl galantamine 56 Adrenergic 56 invasive candidiasis 56 Placebo Controlled Study 56 Epstein Barr virus EBV 56 Upregulation 56 Spinal Muscular Atrophy SMA 56 daptomycin 56 administered concomitantly 56 gemcitabine Gemzar ® 56 Autoimmune Disorders 56 mGluR5 NAM 56 opioid induced constipation 56 trans retinoic acid 56 Systemic Lupus Erythematosus SLE 56 soluble tumor necrosis 56 selective modulator 56 1 antitrypsin AAT 56 Subgroup Analysis 56 hormone LHRH antagonist 56 CIMZIA TM 56 Remicade infliximab 56 subcutaneously administered 56 investigational monoclonal antibody 56 Orphan Status 56 Oral Compound 56 interferon gamma 1b 56 UPLYSO 56 anorexia cachexia 56 Sanfilippo Syndrome 56 remission induction 56 Sanvar R 56 Maroteaux Lamy syndrome 56 overactive bladder syndrome 56 BXT # 56 renin inhibitor 56 Azmacort R 56 Progenitor Cells 56 metastatic hormone refractory 56 Fibroblast 56 Rindopepimut 56 TNF Blockers 56 Bullous 56 Tumor Suppressor 56 recurrent herpes labialis 56 tumor xenograft models 56 metastatic carcinoid 56 Xeloda ® 56 markets HP Acthar 56 stage IIIB 56 LPS induced 56 aldehyde dehydrogenase ALDH2 deficiency 56 Bipolar Mania 56 alpha antagonist 56 Dilated Cardiomyopathy 56 CD# monoclonal antibody 56 anthracyclines taxanes 56 PGL# 56 miconazole Lauriad R 56 Anticancer Compound 56 Allovectin 7 56 Essential Tremor 56 Inhibits 56 JAK inhibitors 56 VEGF inhibitors 56 Advanced Renal Cell 56 Mipomersen 56 bacterium Mycobacterium tuberculosis 56 SUPPRELIN R LA 56 multi kinase inhibitor 56 Clolar ® 56 inhaled liposomal ciprofloxacin 56 receptor partial agonist 56 vascular disrupting agents 56 Glioblastoma Multiforme GBM 56 indinavir Crixivan 56 cytokine refractory 56 Inhalation Aerosol 56 CCR5 antagonist 56 Stage IIB 56 Laquinimod 56 headache abdominal pain 56 lipoglycopeptide 56 lymphoproliferative disorders 56 Cannabinoid 56 Paroxysmal 56 Kepivance 56 CD# CEA 56 octreotide acetate 56 antibody MT# 56 ProMune 56 OvaRex R 56 leukemia CLL 56 refractory CLL 56 MGd 56 elvucitabine 56 samarium Sm 56 memantine HCl 56 Phase IIA 56 progressive neurodegenerative disorder 56 #/#mg 56 homozygous FH 56 superficial basal cell carcinoma 56 sublingual tablets 56 dyskinesia PD LID 56 sitagliptin metformin 56 Simulect 56 Pradefovir 56 chronic bronchitis AECB 56 severe gastroparesis 56 Expedited Review 56 castrate resistant prostate cancer 56 ABCB1 56 huC# DM4 56 Ocrelizumab 56 neurological manifestations 56 clotrimazole 56 Zavesca 56 Single Dose 56 ADL# novel 56 Inhalation Solution 56 drug conjugate 56 TASKi3 56 Novel Mechanism 56 Severe Asthma 56 Gonal f R 56 Neimann Pick 56 Receptor Antagonists 56 developing Zerenex ferric 55 HDACi 55 stage IIIb IV 55 Beta Amyloid 55 Portal Hypertension 55 Oncogenic 55 rasagiline tablets 55 ATL# [001] 55 Estrogen Receptor 55 gabapentin Neurontin 55 Panzem R 55 AGGRASTAT R Injection tirofiban 55 Neurological Diseases 55 GSK# [001] 55 metastatic bladder 55 Fungal Infections 55 hydroxamic acid 55 Cancer Cachexia 55 myeloproliferative diseases 55 Clusterin 55 Archexin 55 SGPT 55 tuberous sclerosis TS 55 Chronic Heart Failure 55 retinoic acid receptor 55 juvenile idiopathic arthritis JIA 55 Disord 55 Secondary Hyperparathyroidism 55 Neurogenic 55 Polymorphic Ventricular Tachycardia CPVT 55 imipramine Tofranil 55 administered intranasally 55 Detrol Detrol LA 55 PAOD 55 Cystic 55 non nucleoside 55 initiate Phase IIa 55 investigational humanized monoclonal antibody 55 Launches Generic Version 55 p# MAP kinase inhibitor 55 vWD 55 regulated kinase 55 Cx# [002] 55 primary dysmenorrhea 55 autosomal recessive genetic 55 Retinitis Pigmentosa RP 55 refractory cutaneous T 55 AAT deficiency 55 acute HAE 55 erythema nodosum 55 Hexvix ® 55 diabetic neuropathic pain 55 bronchial hyperresponsiveness 55 autoimmune encephalitis 55 hypophosphatasia 55 Duchenne muscular dystrophy DMD 55 refractory gout 55 FDA Approvable Letter 55 Diabetic Retinopathy DR 55 β thalassemia 55 Syndrome LEMS 55 Cytomegalovirus CMV 55 Ixabepilone 55 Opterone R 55 docetaxel Taxotere R 55 Announces Poster Presentations 55 PDX pralatrexate 55 antiphospholipid syndrome 55 refractory acute promyelocytic 55 HuMax HepC TM 55 EVIZON ™ 55 Bortezomib 55 HCV protease inhibitors 55 DELATESTRYL R 55 Parathyroid Hormone 55 Hedgehog pathway inhibitor 55 interferon alpha IFN alpha 55 fumarate 55 Adenoma 55 cytogenetic abnormalities 55 Curaxin 55 CD3 monoclonal antibody 55 e antigen HBeAg 55 Kit CD# positive 55 maleate 55 Iron Overload 55 polymyalgia rheumatica 55 Faropenem 55 von Hippel Lindau 55 anemias 55 See CLINICAL PHARMACOLOGY 55 alpha#beta# integrin 55 Calixa